Please login to the form below

Not currently logged in


This page shows the latest DSM news and features for those working in and with pharma, biotech and healthcare.

DSM merges pharma unit with Patheon

DSM merges pharma unit with Patheon

New company will provide portfolio of development and manufacturing services. Royal DSM has reached a deal to spin off its pharmaceutical business and merge it with contract development and manufacturing organisation ... The board of directors will

Latest news

  • Big Pharma or Big Food? Insights on the nutraceuticals debate Big Pharma or Big Food? Insights on the nutraceuticals debate

    So with 'the global nutraceutical event', Vitafoods Europe, just around the corner in May it's anyone's guess what sponsors such as Royal DSM and Natural Alternatives International, as well

  • Therapy focus: ADHD

    In Europe, it takes, on average, more than two years (almost 27 months) for parents to reach a diagnosis of ADHD for their child – using DSM-IV criteria (see below). ... The key diagnostic criteria tools currently used to identify ADHD are the

  • Meeting with resistance

    The likely date of clinical trial initiation is unclear. Novacta is working with DSM BioSolutions for manufacture of NVB302 because of DSM's expertise in scaling up fermentation processes for antibacterial

  • News in brief, July 13, 2007

    DSM Biologics and Crucell sign licensing deal with Masterclone. Royal DSM and fellow Dutch biotechnology company Crucell have signed a non-exclusive PER.C6 research licensing agreement with Russian-headquartered Masterclone. ... Crucell and DSM's PER.C6

  • News in brief, June 07, 2007

    AZ buys biologics facility in Canada. AstraZeneca (AZ) has acquired a biologics manufacturing facility in Montreal, Canada, from Canadian DSM Biologics.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Risks, reforms and rewards: the evolving Russian healthcare market Risks, reforms and rewards: the evolving Russian healthcare market

    Value of the market. The Russian pharmaceutical market was worth 1, 682bn roubles in 2018, which is 2.6% higher than the previous year, according to analysis by DSM Group. ... According to DSM Group: “Market experts agree that the online sale of

  • Pharma deals during September 2014 Pharma deals during September 2014

    The contract manufacturing sector is in a state of flux with the acquisition of Patheon last year by DSM and Akorn's acquisition of the ophthalmic manufacturer Excelvision in July this

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    1, 017. Patheon / Royal DSM and JLL Partners. Merger and acquisition. ... DSM and JLL Partners (private equity) acquire. Patheon and merge it with DSM's CMO Pharmaceutical Products Division in a jointly owned Newco.

  • Country report: The healthcare market in Brazil Country report: The healthcare market in Brazil

    The need for anti-depressants is increasing rapidly in emerging markets, including Brazil, where the prevalence of DSM-IV major depressive episodes was 10.4 per cent in a 12-month

  • Interview: Stephan Tanda, EuropaBio Interview: Stephan Tanda, EuropaBio

    It was DSM's strategy of using biotechnology across its pharma, food and industrial activities that drew Stephan Tanda to join the Netherlands-based company in 2007. ... DSM's CEO had been one of the founding fathers of the organisation back in 1996,

More from intelligence
Approximately 1 fully matching, plus 4 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...